Financial

Conavi Medical Corp. Announces Pricing of Public Offering of Common Shares and/or Pre-Funded Warrants

Financial by 0 comments

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES FINAL PROSPECTUS WILL BE ACCESSIBLE ON SEDAR+ TORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce the pricing and terms of its previously announced public offering. The offering is of common shares of the Company (“Common Shares”) and/or pre-funded common share purchase warrants of the Company (“Pre-Funded Warrants” and, together with the Common Shares, the “Securities”) in lieu of Common Shares (the “Offering”). The Offering is being conducted on a commercially reasonable efforts agency basis for the issuance of a minimum of 33,333,333 Securities and a maximum of 44,444,444 Securities at a price of $0.45 per Common Share or $0.44999 per Pre-Funded Warrant, for gross proceeds of between $15,000,000 and $20,000,000. Each Pre-Funded Warrant issued in lieu of a Common Share at the election of any purchaser entitles the holder thereof to acquire one Common Share at an exercise price of $0.00001 per Common Share. The Pre-Funded Warrants will not expire and may be exercised on a “net” or “cashless” basis. The Company intends to use the net proceeds from the Offering to obtain US FDA 510(k) clearance of the next generation Novasight Hybrid system, as well as complete a limited market release and initiate a broader commercial launch in the United States. The Company also intends to use the net proceeds for working capital and other general corporate purposes. The Offering is expected to be completed pursuant to the terms and conditions of an agency agreement entered into between the Company and Bloom Burton Securities Inc. (the “Agent”). The Company is expecting to file today, on December 18, 2025, a final short form prospectus (the “Final Prospectus”) with the securities regulatory authorities in the provinces of Alberta, British Columbia, and Ontario. There will not be any sale of Securities until a receipt for the Final Prospectus has been issued. The Offering may be completed in one or more tranches and is expected to close initially on or about December 23, 2025, or such other date as may be mutually agreed to by the Company and the Agent (the “Closing Date”). The Offering is subject to the satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals, including approval of the TSX Venture Exchange (“TSXV”). The Company will pay to the Agent a cash fee equal to 6.5% of the gross proceeds raised under the Offering, and grant the Agent compensation options equal to 6.5% of the aggregate number of Securities issued under the Offering (the “Compensation Options”), provided however the Agent will receive a reduced cash commission of 3.25% and no Compensation Options in respect of Securities sold to certain purchasers on a president’s list to be agreed to between the Company and the Agent. Each Compensation Option shall entitle the holder to buy one Common Share at the same price per Common Share as under the Offering. The Compensation Options shall be exercisable until that date which is 24 months following the Closing Date. In addition, the Securities are anticipated to be offered by way of private placement in certain jurisdictions outside of Canada pursuant to and in compliance with applicable securities laws. This press release is not an offer to sell or the solicitation of an offer to buy the Securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The Securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and such Securities may not be offered or sold to, or for the account or benefit of, persons in the United States or U.S. persons except pursuant to an exemption from the registration requirements under the U.S. Securities Act and applicable U.S. state securities laws. “United States” and “U.S. persons” have the meanings ascribed to them in Regulation S under the U.S. Securities Act. Access to the Final Prospectus and any amendments to such documents will be provided in accordance with securities legislation relating to procedures for providing access to a short form prospectus and any amendment thereto. The Final Prospectus (when filed) will be accessible on SEDAR+ at www.sedarplus.ca. Alternatively, an electronic or paper copy of the Final Prospectus (when filed), as well as any amendment to such documents, may be obtained without charge from the Agent by email at ECM@bloomburton.com, by telephone at 416-640-7585 or by providing the contact with an email address or address, as applicable. The Final Prospectus (when filed) contains important, detailed information about the Company and the Offering. Prospective investors should read the Final Prospectus (when filed) before making an investment decision. About Conavi Medical Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, enabling simultaneous and co-registered imaging of coronary arteries. The first-generation Novasight Hybrid™ System has 510(k) regulatory clearance in the U.S., Canada, China, and Japan. For more information, visit http://www.conavi.com. CONTACT: Christina Cameron IR@conavi.com Notice on forward-looking statements: This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Conavi and its business, which may include, but are not limited to, statements with respect to the anticipated terms and jurisdictions of the Offering; securities offered thereunder; the timing of the Offering, including the anticipated Closing Date and timing for the Final Prospectus; use of proceeds from the Offering; fees anticipated to be paid to the Agent and terms thereof; and regulatory and exchange approvals, including the listing of the Common Shares offered pursuant to the Offering on the TSXV. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” “anticipate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the Final Prospectus (which, when filed, will be available on the Company’s profile at www.sedarplus.ca). Although Conavi has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Conavi does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Continue Reading →

DeLorean AI Releases New Cardiovascular AI White Paper Showing Predictive AI Can Prevent Heart Failure and Cut Costs by Up to $350,000 Per Patient

Financial by 0 comments

Clinically validated platform delivers predictive precision, empowering clinicians with real-time visibility to reduce preventable complications and improve patient outcomes PALM BEACH, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) — DeLorean AI has announced the release of a new white paper demonstrating that its Cardio AI platform can accurately identify patients at risk of progressing to heart failure before symptoms appear, giving providers a clinically validated tool to intervene earlier and improve outcomes. The analysis, drawn from 12 million patient records, shows DeLorean AI’s models achieve 87% sensitivity in predicting progression toward heart failure, offering payers and providers measurable outcomes that reduce avoidable care costs by as much as $250,000–$350,000 per patient annually. “Value-based care is under enormous pressure right now, as we’ve seen with Optum renegotiating many of its contracts,” said Dr. Severence MacLaughlin, CEO and Founder of DeLorean AI. “If payers, providers, and even agencies like CMS and HHS had predictive visibility into patient deterioration before it happens, these payment structures wouldn’t break down. Predictive AI is the missing infrastructure that allows value-based care to actually work.” Cardiovascular disease continues to drive the highest medical expenditures in the United States, costing $417.9 billion annually and contributing to more than 941,000 deaths each year. Heart failure alone can exceed $350,000 per patient in the year of diagnosis, despite being a condition with a predictable and preventable trajectory when proactive care is implemented. DeLorean AI’s models analyze longitudinal EHR and claim data to deliver predictive precision that gives clinicians a clearer view of patient trajectories now and in the future. Findings from the white paper include: Accurate identification of early deterioration from hypertension or ischemic heart disease toward heart failure with 87% sensitivityPredictive insight into whether a patient’s condition will improve, worsen, or remain stable with 85–87% accuracyPrediction of acute heart failure hospitalization up to 90 days in advance, supporting timely interventionProvide Next Best Actions (NBAs) for licensed professionals to avert adverse events of patients predicted to have a cardiac event, keeping patients out of the hospital and decreasing costs These clinically validated performance metrics equal or surpass those seen in peer-reviewed cardiovascular machine-learning studies, while leveraging a significantly larger dataset. “Predictive and Interventive AI for prevention is now possible at scale,” said Dr. MacLaughlin. “By giving clinicians the power to see risk earlier and in the future, two weeks, four weeks and 8 weeks, we’re enabling hospitals to stay ahead of deterioration and provide care that’s more precise, proactive, and personalized.” Cardio AI integrates with any EHR and keeps providers at the center of care. The platform: Flags patients who may be progressing toward cardiac complicationsIdentifies deviations from ACC/AHA guideline-recommended therapiesSurfaces patient-specific next-best actions rooted in evidence-based medicineSupports primary care physicians and cardiologists with intuitive, accessible intelligence The white paper shows that predictive, preventative care delivers significant value for health systems, insurers, and patients. Managing individuals in pre-event stages such as hypertension (I-10) or chronic ischemic heart disease (I-25) reduces cardiac claims by $60,000–$70,000 per patient annually, while preventing heart failure altogether generates $250,000–$350,000 in savings per patient. With more than three million Americans at elevated risk, predictive intervention represents a pathway to billions in avoidable healthcare spending nationwide. “Technology should amplify human expertise, not replace it,” said Dr. MacLaughlin. “Our platform gives clinicians the clarity and confidence to intervene earlier, reduce preventable complications, and drive better outcomes across entire populations.” DeLorean AI’s approach centers on transparency, clinical validation, and ethical AI. The platform is built for real hospitals, real providers, and real patients, offering precision without overpromising and innovation grounded in medical science. About DeLorean AI: DeLorean AI is a Palm Beach-based healthtech company pioneering predictive artificial intelligence for chronic and acute disease detection. Founded by Dr. Severence MacLaughlin, DeLorean AI develops clinically validated tools that empower healthcare providers to identify at-risk patients earlier, recommend optimal interventions, and dramatically improve outcomes. The company’s platform focuses on key disease areas including cardiovascular disease, chronic kidney disease, end stage renal disease, cardiovascular disease diabetes, COPD, and depression. With seven patents in process and a proprietary model trained on over 80 million patient records, DeLorean AI delivers real-time risk stratification, suggested clinical actions, and future-state predictions, reducing costs and extending lives. As it expands from B2B partnerships to direct-to-patient engagement, DeLorean AI is redefining what’s possible in proactive, data-driven healthcare. Media Contact:Carolina Arguellesinquiries@deloreanai.com Disclaimer: This content is provided by sponsor. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. This content is for informational purposes only and should not be considered financial, investment, or business advice. All business and investment activities involve risks, including the potential loss of capital. Readers are strongly encouraged to perform their own due diligence and consult with a qualified advisor before making any financial decisions. Neither the media platform nor the publisher shall be held responsible for any inaccuracies, misrepresentations, or financial losses resulting from the use or reliance on the information in this press release. Speculate only with funds you can afford to lose. In the event of any legal claims or concerns regarding this article, we accept no liability or responsibility . Globenewswire does not endorse any content on this page. Legal Disclaimer: This media platform provides the content of this article on an “as-is” basis, without warranties or representations of any kind, express or implied. We assume no responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained herein. Any complaints, copyright issues, or inquiries regarding this article should be directed to the content provider listed above. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/93800c5e-3507-41b9-806e-22d6de8c1b24

Continue Reading →

Adagio Medical Appoints Industry Veteran Sean Salmon to Board of Directors

Financial by 0 comments

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Sean Salmon has been appointed to its Board of Directors. Mr. Salmon will also serve on the Company’s Audit Committee and […]

Continue Reading →

Kestra Medical Technologies Reports Second Quarter Fiscal 2026 Financial Results

Financial by 0 comments

KIRKLAND, Wash., Dec. 11, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the second quarter fiscal 2026, which ended October 31, 2025. Financial Highlights Generated revenue of $22.6 million in Q2 FY26, an increase of 53% compared to the prior year period.Expanded gross margin to 50.6% in Q2 FY26 compared to 39.6% in the prior year period.Increased FY26 revenue guidance to $91 million, which would represent growth of 52% compared to FY25. “Kestra delivered another strong quarter of financial performance, generating revenue growth of 53% while expanding gross margin to over 50%, an important milestone for the company,” said Brian Webster, President and CEO. “We also continued to make progress on several key operational objectives, including growing the commercial organization, announcing compelling primary results from our post-approval study at the American Heart Association annual meeting, and fortifying our balance sheet with an equity offering earlier this month. As we progress on our journey to category leadership, our team remains focused on growing the wearable defibrillator market and executing on our commitments to patients and their prescribers.” Second Quarter Fiscal 2026 Financial Results Total revenue was $22.6 million, an increase of 53% compared to the prior year period. 4,696 prescriptions were written for the ASSURE® system, an increase of 54% compared to the prior year period.Revenue growth was driven by higher market share and continuing WCD market expansion. Revenue also benefited from a higher mix of in-network patients and continued improvements in revenue cycle management capabilities. Gross profit was $11.4 million compared to $5.8 million in the prior year period. Gross margin expanded to 50.6% compared to 39.6% in the prior year period, driven by volume leverage and a higher mix of in-network patients. GAAP operating expenses were $43.2 million and included $1.0 million of non-recurring costs. GAAP operating expenses were $25.0 million in the prior year period. Excluding non-recurring costs and share-based compensation expense, operating expenses were $33.5 million in Q2 FY26 compared to $23.8 million in Q2 FY25. The increase was attributable to growth in expenses related to commercial expansion and public company costs. GAAP net loss and comprehensive loss was $32.8 million compared to GAAP net loss and comprehensive loss of $20.6 million in the prior year period. Adjusted EBITDA* loss was $19.7 million compared to an adjusted EBITDA loss of $16.1 million in the prior year period. Cash and cash equivalents totaled $175 million as of October 31, 2025. The above cash and cash equivalents balance does not include the $148 million of net proceeds Kestra received from an underwritten public offering of 6.9 million common shares, which closed on December 4, 2025.   *Adjusted EBITDA is a non-GAAP financial measure. See “Use of Non-GAAP Financial Measures” below for additional information. A reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure is included in this press release. Fiscal Year 2026 Revenue GuidanceKestra is increasing its FY26 revenue guidance to $91 million, which would represent growth of 52% compared to FY25. This compares to prior FY26 revenue guidance of $88 million and initial FY26 guidance of $85 million. Webcast and Conference CallKestra will host a conference call today at 4:30 p.m. ET to discuss financial results. A live and archived webcast of the event will be available in the “Events” section of the investor relations website. Use of Non-GAAP Financial MeasuresThis press release contains certain financial information that is not presented in conformity with U.S. generally accepted accounting principles (“GAAP”), including Adjusted EBITDA. The non-GAAP financial measures are provided as supplemental information to Kestra’s financial measures presented in this press release that are calculated and presented in accordance with GAAP.  Adjusted EBITDA, which is calculated as net income (loss), as adjusted to exclude other income/expense (including interest), income tax expense (benefit), depreciation and amortization expense, share-based compensation expense, and non-recurring new public company costs, is presented because management believes it allows investors to view the Company’s performance in a manner similar to the method used by management to evaluate the Company’s performance for both strategic and annual operating planning. Management believes that in order to properly understand short-term and long-term financial trends, it is helpful for investors to understand the impact of the items excluded from the calculation of Adjusted EBITDA, in addition to considering the Company’s GAAP financial measures. The excluded items vary in frequency and/or impact on our results of operations and management believes that the excluded items are not reflective of our ongoing core business operations and financial condition. Excluding such items allows investors and analysts to compare our operating performance to other companies in our industry and to compare our period-over-period results.  The non-GAAP financial measures used by Kestra may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Kestra’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business. A reconciliation of Adjusted EBITDA reported in this press release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA” later in this release. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Forward-Looking StatementsExcept where otherwise noted, the information contained in this press release is as of December 11, 2025. Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects; and expectations for our products. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Kestra’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; risks and uncertainties related to market conditions; and other risks and uncertainties, including those described under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended April 30, 2025 and other filings filed or to be filed with the U.S. Securities and Exchange Commission (“SEC”). These filings, when made, are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com.  KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share amounts)(unaudited)  Three Months Ended October 31,  Six Months Ended October 31,  2025  2024  2025  2024             Revenue$22,565  $14,710  $41,937  $27,492 Cost of revenue 11,141   8,880   21,661   17,462 Gross profit 11,424   5,830   20,276   10,030 Operating expenses:           Research and development 4,878   3,509   8,878   6,913 Selling, general and administrative 38,301   21,455   72,029   40,682 Total operating expenses 43,179   24,964   80,907   47,595 Loss from operations (31,755)  (19,134)  (60,631)  (37,565)Other expense (income):           Interest expense 1,901   2,317   3,814   4,191 Interest income (1,796)  (878)  (3,962)  (915)Other expense (income) 891   40   (1,939)  88 Net loss before provision for income taxes (32,751)  (20,613)  (58,544)  (40,929)Provision for income taxes 34   8   67   15 Net loss and comprehensive loss (32,785)  (20,621)  (58,611)  (40,944)Net loss attributable to non-controlling interest —   (253)  —   (692)Net loss and comprehensive loss attributable to Kestra Medical Technologies, Ltd. (32,785)  (20,368)  (58,611)  (40,252)Less: Undeclared preferred stock dividends —   3,323   —   5,706 Net loss attributable to common shareholders, basic and diluted$(32,785) $(23,691) $(58,611) $(45,958)            Net loss per share attributable to common shareholders, basic and diluted$(0.64) $(1.19) $(1.14) $(2.31)Weighted-average shares of common shares outstanding, basic and diluted 51,376,278   19,885,382   51,340,438   19,885,382  RECONCILIATION OF GAAP NET LOSS AND COMPREHENSIVE LOSS TO ADJUSTED EBITDA (in thousands)(unaudited)  Three Months Ended October 31,  Six Months Ended October 31,  2025  2024  2025  2024             GAAP Net loss and comprehensive loss$(32,785) $(20,621) $(58,611) $(40,944)Non-GAAP Adjustments:           Interest expense 1,901   2,317   3,814   4,191 Interest income (1,796)  (878)  (3,962)  (915)Other expense (income) 891   40   (1,939)  88 Provision for income taxes 34   8   67   15 Depreciation expense 2,372   1,869   4,401   4,244 Share-based compensation expense 8,653   1,122   13,232   1,499 Non-recurring expenses 1,048   —   3,914   — Adjusted EBITDA$(19,682) $(16,143) $(39,084) $(31,822) KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts)(unaudited)  October 31,  April 30,  2025  2025       Assets     Current assets     Cash and cash equivalents$175,424  $237,595 Accounts receivable, net 10,413   8,081 Disposable medical equipment supplies 6,918   6,572 Prepaid expenses and other current assets 2,659   3,080 Total current assets 195,414   255,328       Right-of-use assets 1,960   2,078 Deposits 1,858   2,021 Restricted cash 334   334 Property and equipment, net 45,932   34,830 Other long-term assets 1,203   1,153 Total assets$246,701  $295,744       Liabilities and Shareholders’ Equity     Current liabilities     Accounts payable$20,209  $23,961 Accrued liabilities 15,494   13,829 Operating lease liabilities, current portion 53   187 Total current liabilities 35,756   37,977       Operating lease liabilities, net of current portion 2,874   3,026 Warrant liabilities 1,977   8,097 Other long-term liabilities 140   140 Long-term debt, net 41,873   41,098 Total liabilities 82,620   90,338       Commitments and contingencies           Shareholders’ equity           Common shares, $1.00 par value; 100,000,000 shares authorized as of October 31, 2025 and April 30, 2025; 51,449,053 issued and outstanding as of October 31, 2025 and 51,348,656 shares issued and outstanding as of April 30, 2025 51,449   51,349 Additional paid-in capital 691,492   674,306 Accumulated deficit (578,860)  (520,249)Total shareholders’ equity 164,081   205,406 Total liabilities and shareholders’ equity$246,701  $295,744  KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)(unaudited)  Six Months Ended October 31,  2025  2024 Cash flows from operating activities     Net loss$(58,611) $(40,944)Adjustments to reconcile net loss to net cash used in operating activities:     Depreciation and amortization 4,401   4,244 Loss on disposal of property and equipment 560   580 Reserve for lost equipment and supplies 901   477 Provision for uncollectible accounts receivable 1,150   1,074 Interest paid-in-kind —   467 Amortization of debt discounts and issuance costs 937   861 Share-based compensation expense 13,232   1,499 Non-cash lease expense 148   242 Change in fair value of warrant liabilities (2,065)  — Changes in operating assets and liabilities:     Disposable medical equipment supplies (596)  (1,117)Prepaid expenses and other current assets 953   (53)Accounts receivable (3,482)  (4,470)Accounts payable (2,372)  (345)Accrued liabilities 520   1,786 Operating lease liabilities (313)  124 Other long-term assets 20   20 Net cash used in operating activities (44,617)  (35,555)Cash flows from investing activities     Purchases of property and equipment (15,431)  (11,484)Deposits for medical rental equipment (338)  (197)Refund of deposits for medical rental equipment: 117   227 Net cash used in investing activities (15,652)  (11,454)Cash flows from financing activities     Proceeds from issuance of redeemable preferred stock —   103,400 Proceeds from issuance of stock to non-controlling interest —   17,100 Deemed dividend for payments to third party on behalf of shareholder —   (1,598)Payment of equity issuance costs: (1,902)  (3,224)Net cash provided by (used in) financing activities (1,902)  115,678 Net increase (decrease) in cash, cash equivalents and restricted cash (62,171)  68,669 Cash, cash equivalents and restricted cash     Beginning of period 237,929   8,583 End of period$175,758  $77,252 Reconciliation of cash, cash equivalents and restricted cash reported in the condensed consolidated balance sheets     Cash and cash equivalents$175,424  $76,918 Restricted cash: 334   334 Cash, cash equivalents and restricted cash$175,758  $77,252 Non-cash investing and financing activities:     Purchases of property and equipment in accrued liabilities and accounts payable$8,313   7,914 Exercise of liability classified warrant 4,055   — Supplemental disclosure of cash flow information     Income taxes paid (refunds received)$(18) $43 Interest paid 2,846   2,451  CONTACT: Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com

Continue Reading →

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Financial by 0 comments

MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, December 17, 2025, at 8:00 a.m. ET to discuss its fiscal year 2025 financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. An archived version of the audio webcast will be available for replay on the Company’s website for approximately three months. A telephonic replay will be available at approximately 12:00 p.m. ET by dialing 1-855-669-9658 (domestic) or 1-412-317-0088 (international), passcode 2225332, for one week. About Veru Inc.Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass leading to improved body composition and physical function with expected clinically meaningful incremental weight reduction versus GLP-1 RA monotherapy. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease.Enobosarm Obesity Program – Enobosarm is a next generation drug that in combination with GLP-1 RA results in higher quality weight reduction The Phase 2b QUALITY clinical study was a positive multicenter, double-blind, placebo-controlled, randomized, dose-finding clinical trial designed to evaluate the safety and efficacy of enobosarm 3mg, enobosarm 6mg, or placebo as a treatment to augment fat loss and to prevent muscle loss in 168 older patients (≥60 years of age) receiving semaglutide (Wegovy®) for weight reduction. After completing the efficacy dose-finding portion of the Phase 2b QUALITY clinical trial ended at 16 weeks, participants continued into a Phase 2b maintenance extension study where all patients discontinued semaglutide treatment, but continued receiving placebo, enobosarm 3mg, or enobosarm 6mg as monotherapy in a double-blind fashion for 12 weeks. The Phase 2b QUALITY and Maintenance Extension clinical trial was a positive study that demonstrated that preserving lean mass and physical function with enobosarm plus semaglutide led to greater fat loss during the 16 week active weight loss period for a higher quality weight reduction compared to the placebo group. While weight loss was similar across treatment groups in this short 16 week study, we anticipate that preservation of lean mass and function will lead to increased energy expenditure, and this effect coupled with the direct effects of enobosarm on the additional selective reduction in fat mass will result in incremental weight reduction in a longer clinical study in patients who have obesity. Phase 2b PLATEAU clinical studyVeru’s planned Phase 2b PLATEAU clinical study will evaluate the effect of enobosarm 3mg on total body weight, physical function, and safety in approximately 200 patients who have obesity (BMI ≥ 35) and are initiating GLP-1 RA treatment for weight reduction. The primary efficacy endpoint of the study is the percent change from baseline in total body weight at 72 weeks. An interim analysis will be conducted at 36 weeks to assess the percent change from baseline in lean body mass and fat mass, as measured by DEXA scans. The key secondary endpoints are total fat mass, total lean mass, physical function (stair climb test), bone mineral density, and patient reported outcome questionnaires for physical function (SF-36 PF-10, and IWQOL-lite CT physical function). The Phase 2b PLATEAU clinical study is designed to assess the ability of enobosarm treatment to break through the weight loss plateau observed in patients with obesity receiving GLP-1 RA treatment to achieve clinically meaningful incremental weight reduction and preserve muscle mass and physical function by 72 weeks. The clinical study is expected to begin in calendar Q1 2026. Forward-Looking StatementsThis press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, express or implied statements related to the planned design, enrollment, timing, commencement, interim and full data readout timing, scope and regulatory pathways for the continued development of enobosarm in patients with obesity, including the planned PLATEAU Phase 2b study; whether clinically meaningful incremental weight loss in the PLATEAU Phase 2b study will continue to be seen as an acceptable primary endpoint by the FDA to support potential approval; whether the FDA will continue to accept 3mg as an acceptable dosage for enobosarm in the planned PLATEAU Phase 2b study or in any other studies; whether the FDA will further evolve its position on the acceptable patient population for the PLATEAU Phase 2b study or any other future studies; whether the Company will be able to partner with any other company in the development of enobosarm; whether the results of the Phase 2b QUALITY study and the extension maintenance study of enobosarm, including weight loss, preservation of lean mass and function, will be replicated to the same or any degree in the planned PLATEAU Phase 2b study or in any future Phase 3 studies; whether patients treated with enobosarm in the planned PLATEAU Phase 2B study will exhibit increased energy and whether such effects will result in incremental weight reduction; whether patients treated with enobosarm in the planned PLATEAU Phase 2B study will exhibit higher quality weight reduction; the expected costs, timing, patient population, design, endpoints and results of the planned PLATEAU Phase 2b study or any future Phase 3 studies of enobosarm in patients with obesity; whether the Company will be able to raise sufficient capital, dilutive or otherwise, to fund the PLATEAU Phase 2b study of enobosarm in patients with obesity or any other studies; whether the Company will be able to recruit a sufficient number of patients in a timely manner for the PLATEAU Phase 2b study; whether the Company will be able to obtain sufficient GLP-1 RA drugs in a timely or cost-effective manner in the planned PLATEAU Phase 2b study or any future Phase 3 studies; whether the Company will be able to engage clinical research organizations and recruit patients for the PLATEAU Phase 2b program and in a timely or cost-effective manner; whether enobosarm will cause weight loss or preserve muscle in, or meet any unmet need for, obesity patients and whether it will cause weight loss in the planned PLATEAU Phase 2b study or any future Phase 3 studies or, if approved and commercialized, in clinical practice; whether patients treated with enobosarm for a longer period of time than in the Phase 2b QUALITY study will experience weight loss or have a greater loss of adiposity or greater weight loss than with GLP-1 RA drug alone; whether and when enobosarm will be approved by the FDA as a weight loss drug or a body composition drug or any other type of drug; and whether and when the Company will be able to further advance the development of sabizabulin in atherosclerotic disease. The words “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “opportunity,” “plan,” “predict,” “potential,” “estimate,” “should,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based upon current plans and strategies of the Company and reflect the Company’s current assessment of the risks and uncertainties related to its business and are made as of the date of this press release. The Company assumes no obligation to update any forward-looking statements contained in this press release because of new information or future events, developments, or circumstances. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and if any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to: the development of the Company’s product portfolio and the results of clinical studies possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; although the Company has sought and received feedback from FDA on the designs of its clinical trials and intends to continue to do so, FDA may ultimately disagree that the Company’s trials support approval; the Company’s ability to reach agreement with FDA on study design requirements for the Company’s planned clinical studies, including for the Phase 2b program for enobosarm as a weight loss or body composition drug and the number of future Phase 3 studies to be required and the cost thereof; potential delays in the timing of and results from clinical trials and studies, including as a result of an inability to enroll sufficient numbers of subjects in clinical studies or an inability to enroll subjects in accordance with planned schedules; the ability to fund planned clinical development as well as other operations of the Company; the timing of any submission to the FDA or any other regulatory authority and any determinations made by the FDA or any other regulatory authority; the potential for disruptions at the FDA or other government agencies to negatively affect our business, including as a result of a future shutdown of the U.S. government; any products of the Company, if approved, possibly not being commercially successful; the ability of the Company to obtain sufficient financing, including any partnership or collaboration agreements, on acceptable terms when needed to fund development and operations and to enable us to continue as a going concern; demand for, market acceptance of, and competition against any of the Company’s products or product candidates; new or existing competitors with greater resources and capabilities and new competitive product approvals and/or introductions; changes in regulatory practices or policies or government-driven healthcare reform efforts, including pricing pressures and insurance coverage and reimbursement changes; the Company’s ability to protect and enforce its intellectual property; costs and other effects of litigation, including regulatory challenges, product liability claims, intellectual property, securities litigation and litigation with the purchaser of the Company’s FC2 business; the Company’s ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company’s ability to successfully integrate acquired businesses, technologies or products; and other risks detailed from time to time in the Company’s press releases, shareholder communications and Securities and Exchange Commission filings, including the Company’s Form 10-K for the year ended September 30, 2024, and subsequent quarterly reports on Form 10-Q. These documents are available on the “SEC Filings” section of our website at www.verupharma.com/investors.Wegovy® is a registered trademark of Novo Nordisk A/S. Investor and Media Contact:Samuel FischExecutive Director, Investor Relations and Corporate CommunicationsEmail: veruinvestor@verupharma.com 

Continue Reading →

Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate

Financial by 0 comments

Gosselies, Belgium, 10 December 2025 (08:30 am CET) – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, has raised €5.5 million in a Series A extension funding round, enabling the company to continue preparations to launch a potentially registrational Phase 2b trial of its lead candidate BIOX-101 to treat intracerebral hemorrhage (ICH) in 2027. Newton Biocapital, a specialist life science venture capital firm focusing on early-stage companies in Europe and Japan, entered as a new investor, together with other new and existing shareholders, bringing the total Series A financing to about €17.5 million.

Continue Reading →
1 2 3 4 5 … 470